Today: 1 July 2026
Browse Category

NYSE:JNJ 16 December 2025 - 26 December 2025

Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

Johnson & Johnson (JNJ) Stock: What to Know Before the Market Opens on Dec. 26, 2025

U.S. markets reopen for a full session on Friday, Dec. 26, 2025, following the Christmas Day closure—after a holiday-shortened early close on Wednesday, Dec. 24. New York Stock Exchange+1 For Johnson & Johnson investors, the post-holiday open comes with a familiar mix of defensive-stock appeal and headline risk—especially around talc litigation, Washington drug-pricing pressure, and the company’s portfolio reshaping plans. Below is a detailed, publication-ready rundown of the most important news, forecasts, and analysis to know before the bell.
26 December 2025
·
Johnson & Johnson Stock After Hours Today (Dec. 25, 2025): JNJ Holds Near $208 — What to Know Before the Market Opens Dec. 26

Johnson & Johnson Stock After Hours Today (Dec. 25, 2025): JNJ Holds Near $208 — What to Know Before the Market Opens Dec. 26

Johnson & Johnson is in an unusual “after the bell” setup today: there is no U.S. closing bell on Dec. 25 because the New York Stock Exchange is closed for Christmas Day, following a scheduled early close on Wednesday, Dec. 24. New York Stock Exchange+1 That means the most relevant read for investors heading into Friday, Dec. 26, 2025 is the last available close and after-hours quote from Dec. 24, plus the headline risks that can hit the tape while markets are shut.
25 December 2025
·
Johnson & Johnson Stock (JNJ) Update: Price, Latest News, Analyst Forecasts and Key Risks on December 25, 2025

Johnson & Johnson Stock (JNJ) Update: Price, Latest News, Analyst Forecasts and Key Risks on December 25, 2025

December 25, 2025 — Johnson & Johnson stock is in “holiday mode” today, with U.S. markets closed for Christmas Day after an early close on Christmas Eve. Investopedia The last regular-session print before the holiday was $207.78, keeping JNJ near the upper end of its 2025 range. Nasdaq+1 That calm surface hides a busy catalyst stack that investors are carrying into the final trading days of 2025 and the first earnings checkpoint of 2026: fresh talc verdict headlines, new FDA-related momentum, Washington drug-pricing politics, and a steady drumbeat of analyst price-target revisions.
25 December 2025
·
Johnson & Johnson Stock After the Bell Dec. 24, 2025: JNJ Holds Near $208 — Key News, Forecasts, and What to Watch Before the Next Market Open

Johnson & Johnson Stock After the Bell Dec. 24, 2025: JNJ Holds Near $208 — Key News, Forecasts, and What to Watch Before the Next Market Open

Johnson & Johnson finished the Christmas Eve trading session higher and stayed steady after the close, with holiday-thinned volume shaping how investors should read any late-day moves. As of the latest after-hours update on Wednesday, December 24, 2025, JNJ was trading around $207.78, up roughly 0.95% from the prior close. The stock’s day range was about $205.43 to $207.92, with volume near 2.38 million shares—notably lighter than a typical full session.
24 December 2025
··
Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson Stock Today: JNJ Holds Near $207 on Dec. 24, 2025 as Talc Verdict, Drug-Price Pressure and Q4 Earnings Take Center Stage

Johnson & Johnson is trading through a holiday-shortened Christmas Eve session with investors balancing a familiar mix of defensive appeal and headline risk. On Wednesday, December 24, 2025, J&J shares hovered around $207 in late-morning trade, keeping the healthcare bellwether close to its recent highs even as the company faces fresh legal scrutiny and renewed policy pressure on U.S. drug pricing. StockAnalysis The immediate backdrop matters: U.S. markets are closing early at 1 p.m. ET for Christmas Eve, a schedule that can amplify moves and distort volume signals—especially for mega-caps like J&J that often act as “parking spots” for cautious capital. Investopedia+1
24 December 2025
···
Johnson & Johnson Stock After Hours Dec. 23, 2025: JNJ Slides on Record Talc Verdict — What to Know Before Wednesday’s Open

Johnson & Johnson Stock After Hours Dec. 23, 2025: JNJ Slides on Record Talc Verdict — What to Know Before Wednesday’s Open

Johnson & Johnson ended Tuesday’s session lower and traded narrowly after the closing bell as investors digested a fresh—and record-size—legal headline tied to the company’s long-running talc litigation. With U.S. markets heading into a holiday-shortened session on Wednesday, December 24, the near-term setup is as much about liquidity and headline risk as it is about fundamentals. JNJ finished regular trading on Tuesday, December 23, 2025 at roughly $205.7, down about 0.8% on the day. In extended trading, the stock was little changed to modestly higher, depending on the data feed—hovering in the mid-$205s to low-$206s during the early evening hours. MarketBeat+1
24 December 2025
·
Johnson & Johnson Stock (JNJ) Slips After Record $1.5B Talc Verdict: News, Forecasts, and What to Watch Into 2026

Johnson & Johnson Stock (JNJ) Slips After Record $1.5B Talc Verdict: News, Forecasts, and What to Watch Into 2026

Johnson & Johnson Stock Slips After Record $1.5B Talc Verdict: News, Forecasts, and What to Watch Into 2026 Johnson & Johnson ended Tuesday, December 23, 2025, in the spotlight for reasons that cut both ways for investors: a headline-grabbing talc-related jury verdict that revived long-running legal risk concerns—and a steady drumbeat of regulatory and product updates that reinforce the company’s growth narrative across Innovative Medicine and MedTech.
23 December 2025
··
Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching

Kenvue Inc. is trading in a very particular kind of gravity field on December 23, 2025: part consumer-health staple, part legal-headline lightning rod, and—most importantly right now—part merger-arbitrage instrument because of its pending acquisition by Kimberly-Clark. As of the latest U.S. session data available Tuesday, KVUE traded around $16.98, while Kimberly-Clark traded around $99.97.
23 December 2025
···
Johnson & Johnson (JNJ) Stock After Hours Today (Dec. 22, 2025): After-the-Bell Move, Key Headlines, and What to Watch Before Tuesday’s Open

Johnson & Johnson (JNJ) Stock After Hours Today (Dec. 22, 2025): After-the-Bell Move, Key Headlines, and What to Watch Before Tuesday’s Open

Johnson & Johnson ended Monday’s session modestly higher, and the stock’s after-hours action has been muted so far—typical for a mega-cap defensive name heading into a holiday-shortened week. Still, several active storylines are shaping sentiment tonight, including Washington’s drug-pricing push, fresh talc-litigation developments, and a steady stream of regulatory and pipeline updates that can influence the longer-term bull case. Below is a detailed after-the-bell look at what moved JNJ today and what investors should keep on their radar before the U.S. market opens Tuesday, December 23, 2025.
23 December 2025
·
Johnson & Johnson Stock (JNJ) News Today: Latest Updates, Analyst Forecasts, and What Could Move Shares Next (Dec. 22, 2025)

Johnson & Johnson Stock (JNJ) News Today: Latest Updates, Analyst Forecasts, and What Could Move Shares Next (Dec. 22, 2025)

December 22, 2025 — Johnson & Johnson ends the year with momentum on its side, but not without familiar crosswinds. After a strong 2025 run, investors are balancing a string of late-year regulatory wins and product catalysts against ongoing talc-related litigation headlines—two forces that continue to shape near-term sentiment around Johnson & Johnson stock. As of Monday’s latest available pricing, JNJ shares traded around $206.63.
22 December 2025
·
Johnson & Johnson Stock (JNJ) Before the Market Opens on December 22, 2025: FDA Catalysts, Talc Litigation Headlines, Analyst Targets, and What to Watch

Johnson & Johnson Stock (JNJ) Before the Market Opens on December 22, 2025: FDA Catalysts, Talc Litigation Headlines, Analyst Targets, and What to Watch

Johnson & Johnson heads into the U.S. market open on Monday, December 22, 2025, with investors balancing a familiar mix of defensive-healthcare appeal and headline-driven catalysts—from fresh talc litigation verdicts to FDA-related momentum in oncology and MedTech. Below is what matters most for JNJ stock right now, what analysts are projecting, and which near-term triggers could move shares as the holiday week begins.
22 December 2025
Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

As the market heads into a Christmas-shortened trading week, Johnson & Johnson is entering the final stretch of 2025 with an unusually headline-heavy mix of catalysts: U.S. drug-pricing negotiations tied to the White House, new talc-related jury verdicts, and a string of FDA and clinical updates that reinforce the company’s longer-term growth narrative. As of the latest close, JNJ ended around $206/share, keeping the stock in a tight, late-year range while investors weigh whether policy risk and litigation uncertainty outweigh the steadier benefits of new product momentum and “defensive” healthcare positioning. MarketBeat
21 December 2025
··
Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Dec. 20, 2025 — Johnson & Johnson is closing out the week with investors weighing a fresh talc-related jury verdict, a fast-moving U.S. drug-pricing policy push that could soon reach J&J, and a stream of late-2025 catalysts spanning FDA-related updates, M&A, and a major MedTech restructuring plan. JNJ shares last traded around $206.37, down about 0.9% from the prior close, after touching higher levels earlier in the week.
20 December 2025
·
Johnson & Johnson Stock After Hours Dec. 19, 2025: JNJ Ticks Up After the Bell—Key News, Forecasts, and What to Watch Before the Next Open

Johnson & Johnson Stock After Hours Dec. 19, 2025: JNJ Ticks Up After the Bell—Key News, Forecasts, and What to Watch Before the Next Open

Johnson & Johnson ended Friday’s regular session lower, but the stock moved modestly higher in after-hours trading as investors digested a busy late-day news flow—ranging from Washington drug-pricing headlines to fresh analyst targets and new litigation developments. As of 7:07 p.m. ET on Dec. 19, JNJ was at $207.43 after hours, up $1.06, after closing the regular session at $206.37. Google
20 December 2025
·
Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson Stock News Today (Dec. 19, 2025): Trump Drug-Price Deals, FDA Wins and Fresh $240 Targets Put JNJ in Focus

Johnson & Johnson is back on investors’ radar on Friday, December 19, 2025, as Wall Street digests a fast-moving mix of Washington drug-pricing headlines, a string of U.S. FDA decisions across pharma and medtech, ongoing talc litigation, and a wave of updated analyst price targets. JNJ shares traded around $208 intraday, hovering near the flatline as the market weighed policy risk against company-specific catalysts. MarketScreener
19 December 2025
·
Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open

Johnson & Johnson Stock (JNJ) After Hours Today (Dec. 18, 2025): FDA Approvals, Analyst Targets, and Talc Litigation in Focus Ahead of Friday’s Open

Johnson & Johnson finished Thursday’s regular session lower even as the broader market moved higher, then ticked modestly upward in after-hours trading—leaving investors with a familiar year-end setup: solid pipeline/MedTech progress on one side, and talc litigation headlines on the other. JNJ shares closed the regular session at $208.31, down $2.02, and were slightly higher after hours at about $208.65 in early evening trading. Investing.com
19 December 2025
·
Johnson & Johnson Stock (JNJ) News Today: FDA Approvals, Analyst Price Targets, and the 2026 Outlook (Dec. 18, 2025)

Johnson & Johnson Stock (JNJ) News Today: FDA Approvals, Analyst Price Targets, and the 2026 Outlook (Dec. 18, 2025)

Johnson & Johnson stock traded around $208 on Thursday, December 18, 2025, with shares modestly lower on the session as investors weighed a busy late-year news cycle that includes fresh FDA wins in MedTech and oncology, new Wall Street target updates, and the continued legal overhang from talc litigation. For long-term holders, the story remains familiar: J&J is a diversified healthcare bellwether spanning Innovative Medicine and MedTech—a blend that can cushion volatility, but also means the stock tends to react to a wide mix of regulatory, clinical, litigation, and analyst-driven headlines. Reuters
18 December 2025
·
Johnson & Johnson Stock After Hours (Dec. 17, 2025): JNJ Closes Higher on FDA News—What to Know Before the Market Opens Thursday

Johnson & Johnson Stock After Hours (Dec. 17, 2025): JNJ Closes Higher on FDA News—What to Know Before the Market Opens Thursday

Johnson & Johnson ended Wednesday’s session modestly higher—an eye-catching show of relative strength on a down day for major U.S. indexes—while investors digested a fresh FDA approval tied to the company’s lung cancer franchise and looked ahead to a potentially market-moving inflation print before Thursday’s open. After the closing bell on Dec. 17, 2025, JNJ shares finished at $210.33 and traded slightly higher in after-hours at $210.48. Google
18 December 2025
·
Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

Johnson & Johnson Stock (JNJ) News Today: RBC Raises Target to $240 as FDA Actions and Talc Verdict Shape the 2026 Outlook

CAs of Wednesday, December 17, 2025, Johnson & Johnson is back in focus for investors looking for a “defensive” large-cap healthcare stock—while also weighing two forces that can move JNJ shares quickly: drug pipeline catalysts and talc litigation headlines. JNJ shares are trading around $210 today, after a volatile stretch that included a sharp pullback on Tuesday, December 16, and renewed analyst attention mid-week. StockAnalysis
17 December 2025
·
Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

December 16, 2025 — Johnson & Johnson stock is trading lower on Tuesday after pushing to fresh highs earlier this week, as investors weigh a mix of pipeline momentum, legal headlines, and an approaching earnings update that could clarify the company’s 2026 trajectory. StockAnalysis+1 Below is what’s moving Johnson & Johnson shares right now, what Wall Street is forecasting, and the key dates JNJ stock watchers have on the calendar.
16 December 2025
···
1 … 4 5 6 7 8 9

Stock Market Today

  • White House Rejects Conflict Claims as Trump Crypto Windfall Reaches $1.2B
    July 1, 2026, 8:22 AM EDT. The White House pushed back on conflict-of-interest claims after reports put Donald Trump's crypto earnings at roughly $1.2 billion, mainly from World Liberty Financial and the $TRUMP token. Trump's net worth has jumped from $2.3 billion in 2024 to $6.5 billion in 2026, according to Forbes. White House spokesperson Anna Kelly said Trump and his family have not acted on conflicts of interest. The update landed as a 927-page ethics filing surfaced and political activity picked up, with the Supreme Court issuing rulings on birthright citizenship and transgender athletes. The crypto gains add to Trump's finances as he stays active on the political front.
Go toTop